Paracelsus Paradox and Drug Repurposing for Cancer by Koltai, Tomas
46
Journal of Oncology Research | Volume 03 | Issue 02 | July 2021
Distributed under creative commons license 4.0








Paracelsus Paradox and Drug Repurposing for Cancer
Tomas Koltai*
Former Director of the Centro Gallego Hospital of Buenos Aires, Buenos Aires, Argentina
ARTICLE INFO ABSTRACT
Article history
Received: 27 August 2021
Accepted: 7 September 2021
Published Online: 13 September 2021
Dose is one of the parameters that any pharmacologist seriously considers 
when studying the effects of a drug. If the necessary dose to achieve a 
desired pharmacological effect is in a toxic or very toxic range for human 
use, the drug will probably fall out from further research. The concentration 
that a drug can reach to its target organ or cell is a direct consequence of the 
administered dose and its pharmacodynamic properties. Basic researchers 
investigate at the cellular level or eventually with xenografts. They use 
different concentrations of the drug in order to determine its cellular effects. 
However, in many cases, these concentrations require doses that are in the 
toxic range or well beyond any clinically achievable level. Therefore, in 
these cases, research is in the realm of toxicology rather than therapeutics. 
This paper will show some examples about this exercise in futility which 
is time and resource consuming but that pullulates the pages of many 









If a cell whether normal or malignant is cultured in 
distilled water or even in tap water, the cell will die in a 
short time. Osmolarity in the first place and lack of nu-
trients will be the cause of death. Therefore, we can say 
that pure water is cytotoxic for both normal and malignant 
cells. Now let’s change the circumstances, We give a glass 
of pure water to drink to a normal or sick individual and 
we shall discover that it is neither bad nor good. It has no 
effect and it is not cytotoxic. Finally in a new dramatic 
change of circumstances we administer the same pure 
water, but this time two liters via the trachea and the indi-
vidual will be dead in a few minutes. In the movies, this 
last case would not be considered cytotoxicity but rather 
death by drowning according to the district attorney. In all 
three cases the substance used was plain water. In two out 
of three it was deadly, in one nothing happened.
What kind of a drug is plain water: cytotoxic, neutral or 
deadly? What changed in each occasion were the circum-
stances: applied to the cell, received per os, and finally a 
huge amount received by an unusual administration route.
This little game seems ridiculous, poorly planned and 
undoubtedly absurd. However, this is the way a large pro-
portion of scientific papers work.
When we treat a malignant cell with 1,000 fold the 
highest level statins can achieve in circulation and we 
reach the conclusion that statins can be used as cytotoxic 
for tumors, aren’t we playing the same game as above?
We coined a name for the game: PPP. It is not the Pen-
tose Phosphate Pathway but the Potentiated Paracelsus 
Paradox.
2. Paracelsus Paradox
Sometime in the 1500s Paracelsus, the Swiss alche-
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mist and physician, established that any curative drug 
can at the same time be a poison, depending on the dose. 
We added the Potentiated by modifying one item in the 
Paracelsus Paradox: any curative drug is at the same time 
a poison, depending on the dose and the administration 
route.
Of course, nobody remembers Paracelsus anymore be-
cause he committed three sins:
He lived 500 years ago, did not have a Facebook page, 
and last but not the least, wrote in vulgata, sort of a bad 
Latin, today’s equivalent of the most popular language in 
science, bad English.
PPP may be a good game for children, but does it have 
anything to do with the twenty-first century hard science?
If we are supposedly scientist let’s examine the evi-
dence before arriving at any conclusions.
3. Statins
We shall start by examining statins. There are many 
publications maintaining that statins have an anti-tumoral 
effect. Most of these papers are based on in vitro studies. 
However, these experiments may be misleading, because 
excessively high concentrations of statins were used, 
which cannot be reached in patients or if they are reached it 
would be at the expense of serious toxicity [1]. For example:
►Simvastatin concentration in plasma is in the mean 
range of 2.2-4.3 nM after an oral administration of 40 
mg. The maximum concentration that can be achieved is 
19-31 nM [2]. In a publication, in vitro, simvastatin at 20 
μM induced breast cancer cell apoptosis [3]. This level is 
almost 1,000-times higher than the maximum that can be 
achieved in patients. The achievable plasma concentration 
of simvastatin was published in 2009 (probably there are 
prior determinations too). The researchers who used a 
1,000 higher concentration published their results in 2012. 
This means that during all their experimental period they 
knew perfectly well that they were working in the realm 
of fantasy. A few questions are unavoidable:
Did the peer review process make no objections?
Have the 93 citations of this article in nine years taken 
for granted that simvastatin is a tumor apoptogenic drug 
without any further doubt?
Isn’t using 1,000 fold the maximum achievable level of 
the drug like administering four liters of tap water through 
the trachea?
May be PPP is not a fantasy game but part of a game 
researchers like to play. 
► Similarly, Hoque et al. [4] found that statins were 
able to induce apoptosis in prostate cancer cells when they 
were exposed to lovastatin at a concentration of 2 μM. 
However, a dose of 80 mg reaches a maximum concentra-
tion of 50 nM with an average of 9.4 nM [5]. The concen-
tration used by Hoque et al. was 400-fold grater than what 
can be achieved in a patient. To this we must add that 
statin concentration in tissues, with the exception of the liver, 
are much lower than in serum [6]. Thus, most of these effects 
seen in vitro, are with concentrations many fold higher than 
those achievable in patients. Part of the game? 
► Zhuang et al. [7] investigated the effects of lower-
ing lipid rafts’ cholesterol with simvastatin. They found 
that it reduced PI3K/Akt pathway signaling and induced 
apoptosis in LNCaP prostate cancer cells. Cholesterol 
replenishment activated Akt signaling and avoided apop-
tosis. Unfortunately, they used simvastatin concentrations 
of 20 μM, a level impossible to achieve in patients. This 
seminal finding clearly shows the mechanism by which 
cholesterol has an anti-tumorigenic behavior, but due to 
the excessively high simvastatin concentration it does not 
allow possible therapeutic conclusions. Simvastatin, as 
important as it is, is also a poison at very high concen-
trations, following Paracelsus principle: sola dosis facit 
venenum. Therefore, an unanswered question remains: can 
statins have the same effects at the concentrations they 
reach in human beings?
► Wong et al. showed that clinically achievable con-
centrations of statins had the ability to induce apoptosis in 
malignant cells through down-regulation of the anti-apop-
totic protein bcl-2 [8,9]. The pro-apoptotic effect of statins 
was confirmed in many different tumor cell lines, includ-
ing juvenile monomyelocytic leukemia [10], acute myeloid 
leukemia [11], myeloma [12], mesothelioma, pancreatic, 
colon [13], and prostate cancers [14], among others. Howev-
er, when these experiments were analyzed in depth, the 
concentrations of lovastatin used were at the micromolar 
level while the achievable concentrations are in the na-
nomolar levels. This level is not feasible in the clinical 
setting. Thus, the tumor apoptotic effects of statins remain 
controversial [15]. 
► There are also experiments that take into account the 
achievable level of statins in blood. For example, Gordon 
et al. [16] administered oral simvastatin to LNCaP xeno-
graft bearing castrated mice and the plasma level reached 
an average concentration of 3.29 nM without biochemical 
signs of toxicity. This level is found in humans taking 80 
mg of the statin. The dose was effective to slowdown tu-
mor growth and progression. Cholesterol de novo synthe-
sis was also reduced. Can this be extrapolated to humans?
“Unfortunate” concentrations of statins raise doubts 
about the usefulness of some experiments and publica-
tions, but this does not preclude that in spite of these 
poorly planned experiments, the drug may have some an-
ti-tumor effects.
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► Staying with statins let’s go one step further. Many 
publications base the antitumoral action of statins on its 
ability to inhibit Ras farnesylation. Statins are inhibitors 
of HMG-CoA reductase, thus inhibitors of de novo choles-
terol synthesis through the inhibition of mevalonate gener-
ation. Reducing cholesterol synthesis leads to a lower pro-
duction of farnesylate which would decrease farnesylation 
of RAS and Rho GTPases and decrease its activation [17-20]. 
This mechanism is clearly anti-tumoral. However, it only 
works with very high concentrations of statins (50 μM). 
Surprisingly, Cho et al. [18] found that therapeutic levels of 
lovastatin, usually with a concentration range of 50 to 500 
nanomoles (nM), not only did not decrease RAS activa-
tion, but increased it. This occurred as a consequence of 
phospholipase D activation. Therefore, therapeutic levels 
of lovastatin did not decrease RAS prenylation. In spite of 
this seminal finding, most of the publications repeat the 
mantra that statins decrease RAS signaling. This would 
only be true if highly toxic levels of statins were to be ad-
ministered. This does not happen in patients treated with 
statins.
4. Metformin
Metformin is another paradigmatic drug to be repur-
posed almost for everything: aging, obesity, endometrio-
sis, and fundamentally for cancer.
Since Evans et al. [19] in 2005, published their popula-
tion-based statistical finding that metformin reduced the 
risk of cancer in diabetics, tons of papers have been pub-
lished on this subject. Among half true and half erroneous 
concepts, some authors never really read the publication.
For example, an oncology book on repurposed drugs 
references the Evans manuscript saying that metformin 
has been used to treat cancer [20]. The Evans paper is a sta-
tistical study that shows a risk reduction of cancer in dia-
betics taking metformin for the treatment of diabetes, not 
for treating cancer. However, the authors say: “In 2005, 
MTF was used for breast cancer treatment.”
These types of errors are not the focus of this manu-
script. Let’s analyze whether the research backing met-
formin as an “onco” drug is based on solid evidence.
What is the maximum non-toxic concentration of 
metformin?
Administering 500 mg of oral metformin to healthy 
volunteers the plasma concentration of metformin reached 
a maximum level of 1.42 μg/ml after two hours [21]. The 
usual daily dose does not exceed 3 g and the maximum 
approved total daily dose for diabetes mellitus is 2.5 g (35 
mg/kg body weight) [22].
The concentration of metformin is high in the hepatic 
portal vein (approximately double than in cava vein), but 
after it emerges from the liver, the systemic plasma con-
centration is in the range of 10–40 μM in mice [23].
Reviewing the literature there is a wide range of met-
formin concentration in plasma which goes from 0.1 to 4 
mg/l [24]. Therefore, we can assume 4 μg/ml to be the fair 
value. The molecular weight of metformin is 129.16 g/
mol. We will use the maximal non-toxic concentration, 50 
mg/l in humans (0.4 mM or 50μg/ml) as the upper limit of 
metformin that can be clinically reached with oral admin-
istration [25].
CONVERSION TABLE
4 μg/ml = 4 mg/liter = 0.004 g/l achievable plasma 
concentration with 500 mg metformin.
160 mg/liter was found in patients developing lactic 
acidosis with a mortality of 53% [26].
Molecular weight of metformin = 129.16 g/l
A solution with 1 Mol of metformin is a solution that 
contains 129.16 g/liter
1 mM of metformin is 129.16/1000 = 0.129 g/l = 129 
mg/l = 129 μg/ml
Based on these data we analyzed some publications on 
metformin activity in cancer.
► Zhang et al. [27] studied the effect of 5 mM of met-
formin on CD133+ cells in colon cancer and arrived at the 
conclusion that “Inhibition of the proliferation of CD133+ 
cells may be a potential mechanism responsible for the as-
sociation of metformin use with improved CRC outcomes 
in CRC patients with type 2 diabetes”. 5 mM of metform-
in is the equivalent to 645 mg/l. This represents ~13-fold 
increase of what is a clinically achievable non-toxic con-
centration in plasma. To this we must add that the plasma 
concentration is always much higher than tumor concen-
tration.
► Kim et al. [28] tested HeLa cells incubated with met-
formin. They found a decrease in proliferation starting 
at a concentration of 5 mM and from there on in a dose 
dependent manner. Again, the metformin concentrations 
were well beyond toxic levels.
► Jang et al. [29] used metformin for bladder cancer 
cells. A slight decrease of viability could be seen with 
metformin concentration of 3 mM. A clear drop in viabil-
ity was only seen with concentrations between 9 and 12 
mM. We are again in levels that are 20-fold higher than a 
tolerable dose.
► Griss et al. [30] showed that metformin decreased 
cancer cell proliferation in vitro, however they used con-
centrations between 2.5 and 10 mM.
DOI: https://doi.org/10.30564/jor.v3i2.3649
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The above mentioned publications were not select-
ed, but randomly picked from Google Scholar under the 
search based on “metformin and cancer”. 
We are not saying here that metformin has no anti-can-
cer activity, as a matter of fact we believe exactly the 
opposite. The only objective is to show that many of the 
molecular mechanisms published as the fundamentals for 
metformin’s anti-cancer effects, are based on concentra-
tions that are absolutely impossible to achieve in patients. 
In vitro studies at poisonous levels, brings us back to Par-
acelsus concept and lack practical bedside application.
5. Capsaicin
It has been shown that capsaicin, present in hot peppers 
and chilli, has interesting anticancer effects. The most im-
portant seem to be promoting apoptosis in cancer but not 
in normal cells [31]. The anti-growth effects of capsaicin 
has been found in androgen- independent prostate can-
cer [32], squamous cell carcinoma KB cells [33], gastric [34], 
pancreatic [35], breast [36,37], colorectal [38,39], small cell lung 
cancer [40] cells among many others.
In spite of all this evidence favoring capsaicin, low 
concentrations have the ability to promote metastasis [41].
A research on capsaicin effects on renal cell carcinoma 
cells [42] showed that it had pro-apoptotic effects at an average 
concentration of 200 μM. One of the peer reviewers asked:
“Significant effect of Capsaicin was seen starting at the 
dose of 200 uM. What is the physiologically achievable 
concentration of capsaicin in Humans?” 
Interestingly, the authors were unable to give a straight 
answer. They said: “Lots of papers studied capsaicin at 
the concentration of 200 uM [1-3] (even 500uM [4]) in 
vitro cell models”.
This means that they used 200 μM (equivalent to ap-
proximately 61 mg/ml. Capsaicin’s molecular weight is 
305 g/mol).) because other authors used the same con-
centration or even higher, but we still do not know if this 
concentration is clinically achievable. The only guide 
we found is that capsaicin in rats can reach 90 ng/ml in 
blood, 167 pg/mg in the lung and 3.4 pg/mg in the liver 
[43]. Suresh et al. [44] found an average concentration of 1.9 
μg/ml after an hour of a high intake of capsaicin in rats. This 
level halved after another hour. In men, after a high intake of 
capsaicin containing food a level of 179 ng/ml was found [45].
Therefore, a concentration of 200 μM is far beyond 
the concentration found in rats and in humans. Prima fa-
cie, it seems very doubtful that 200 μM can be clinically 
achieved.
6. The Wrong Route
A different case is fenofibrate. This lipid lowering drug 
has clearly established antitumoral abilities [46], although 
not all the mechanisms are clearly known. Interestingly, 
there is a great deal of research going on regarding fenofi-
brate’s activity on glioblastoma cells. We summarized 
them in Table 1.
From Table 1 the first conclusion would be that fenofi-
brate should be a first line treatment for glioblastoma. 
Furthermore, PPARα overexpression was found to be as-
sociated with a better prognosis in wild type glioblastoma 
[56] and precisely fenofibrate is a PPARα agonist.
However, there is a problem that some authors seem to 
forget: “fenofibrate does not cross the blood brain barrier 
and is quickly processed by blood and tissue esterases to 
form the PPARα agonist fenofibric acid, which is prac-
tically ineffective in triggering cancer cell death” [57,58]. 
Therefore until a practical approach to deliver fenofibrate 
into the brain tumor is found, all the research at the cellu-
Table 1: Fenofibrate1’s cytotoxicity on glioblastoma cells
Reference Finding
Reiss et al., 2008 [47] Fenofibrate sensitized glioblastoma cells to cisplatin.
Drukala et al. ,2010 [48] Increased ROS potentiated fenofibrate’s anti-glioblastoma effects. 
Giordano et al., 2012 [49] Fenofibrate induced apoptosis in glioblastoma cells.
Wilk et al., 2012 [50]
25 μM of fenofibrate induced glioblastoma cells G1 arrest with minimal apoptosis.. 50 μM achieved massive 
apoptosis. The mechanism was FOXO3 nuclear accumulation that induced BIM (an apoptotic protein) 
transcriptional activation.
Wilk et al., 2013 [51] Anti-tumoral effects of fenofibrate on glioblastoma cells were found to be independent of PPARα agonism.
Binello et al., 2014 [52] They found pro-apoptotic effects and CSCs migration inhibition with fenformin acting on glioblastoma cells.
Han et al., 2015 [53]
Fenofibrate inhibited NF-κB/RelA activation and by impeding its association with hypoxia inducible factor1 
alpha (HIF1α), pyruvatekinase 2 is not expressed, thus favoring oxidative metabolism.
Grabacka et al. ,2016 [54]
Fenofibrate induced the production of ketone bodies in glioblastoma cells that cannot use them as an energy 
source, inducing growth arrest.
Kast et al., 2017 [55]
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lar level will remain in the laboratory. This we have called 
the administration route bias.
However, there are some authors that even recommend-
ed using oral fenofibrate (100 mg twice a day) in the clin-
ical setting for glioblastoma as part of a multidrug scheme 
[59]. Unfortunately, they offer no proof of any benefit.
There is enough evidence to include fenofibrate in a 
clinical trial as a complementary drug for diverse can-
cers, except glioblastoma. As soon as the delivery system 
beyond the blood-brain-tumor barrier for fenofibrate 
becomes reality, this will change. At the present moment 
recommending the unmodified fenofibrate for glioblas-
toma in the clinical setting is at least a poor idea. If there 
are authors that pretend to use unmodified fenofibrate for 
glioblastoma, we wander if they pretend to drill a hole in 
the skull to smear 100 mg twice a day on the tumor. Oth-
erwise, they will only lower triglycerides and we do not 
think that will change the course of events. 
7. Silymarin
Is a compound obtained from milk thisthle (Sibylium 
marianum) that has been used for more than two thousand 
years for the treatment of diverse ailments. Nowadays, 
it is prescribed for the therapy of liver toxicity produced 
by ingestion of Amanita phalloides mushroom, and other 
chemicals and for non-alcoholic liver esteatosis. In the 
last twenty-five years silymarin and its main active prin-
ciple, silybin, has been under scrutiny for the treatment of 
cancer [60]. 
SIL is not soluble in water and oral administration 
shows poor absorption in the alimentary tract (approxi-
mately 1 % in rats [61], however, other authors mention a 
higher absorption around 30%); it is mainly excreted in 
the bile. Toxicity is almost absent [62] and therefore high oral 
doses can be administered with negligible side effects.
In spite of this low absorption, according to Janiak et 
al. a plasma level of 500 mg/L (500 μg/ml) is achievable 
90 minutes after oral administration of 200 mg/kg of sily-
marin in mice [63]. The elimination half-life is 6 hours. 
240 mg of silybin were orally administered to six 
healthy volunteers and the following results were obtained: 
maximum plasma concentration 0.34 ± 0.16 μg/ml and 
time to maximum plasma concentration 1.32 ± 0.45 h. Ab-
sorption half life 0.17 ± 0.09 h, elimination half life 6.32 ± 
3.94 [64].
Beckmann-Knopp et al. [65] found: “Mean maximum 
plasma concentration after an oral dose of 700 mg sily-
marin, containing 254 mg of silibinin, is 317 ng/ml or 0.6 
mM. Accumulation in plasma during three daily medica-
tions is negligible. Plasma protein binding is reported to 
reach about 90–95%”.
Gatti et al. [66] found that free unconjugated silybin 
reached a maximum concentration of 141 ng/ml after 2.4 
hours of feeding volunteers with 80 mg of a lipophilic 
silybin-phospatidylcholine complex (silipide). The level 
of conjugated silybin peaked after 3.8 hours reaching 255 
ng/ml.
Another study on 6 healthy volunteers receiving 560 
mg of silymarin attained concentrations ranging between 
0.18 to 0.64 μg/ml [67].
In dogs [68], the silybin-phosphatidylcholine complex 
(SPC) showed increased concentration when compared 
with silymarin extract, however, the results show a low 
level in general:
SPC: 1,310 ± 880 ng/ml; silymarin: 383 ± 472 ng/
ml.
Morazzoni et al. [69] found higher peak levels of silybin 
in the form of silipide when administered to rats: “After 
oral silipide, silybin reached peak plasma levels within 2 
h, with a Cmax of 9.0±3.0 μg/ml for unconjugated drug and 
93.4±16.7 μg/ml for total (free + unconjugated drug)”.
Concentration in humans (with a low dose) is far lower 
than what was found in rodents (with a high dose). The 
important issue to raise is that most of the experiments at 
cellular level that can be found in the literature use a con-
centration around 100 μg/ml. Even in the publication of 
Morazzoni the level of 100 μg/ml was not achieved and in 
any case it is a peak level that cannot be sustained. There-
fore, is the experimental level achievable at the bedside?
We think that there is no evidence that it can be.
Oral administration of SIL in humans achieves nano-
gram levels but not micrograms. Furthermore, we should 
not extrapolate Morazzoni et al. findings in rats to hu-
mans. 
Therefore, the evidence based on these high concentra-
tion experiments should be cautiously viewed. 
8. Discussion
Five drugs, namely statins, metformin, capsaicin, 
fenofibrate,and silybin are considered in many papers as 
candidates to be repurposed for cancer treatment. The 
first three were used against cancer in in vitro and in vivo 
experiments. Many of the published articles in medical 
literature show that these drugs were essayed in concen-
trations that in most cases are impossible to achieve in 
patients.
The fourth drug, fenofibrate, was proposed at an oral 
dose of 100 mg twice a day for the treatment of glioblas-
toma when this drug is unable to cross the blood-brain 
barrier. Regarding silymarin and silybin the clinically 
achievable concentration may be enough for its antimigra-
tory effects but are insufficient to induce apoptosis.
DOI: https://doi.org/10.30564/jor.v3i2.3649
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Drug repurposing is a growing and useful research ac-
tivity, however we cannot avoid asking how useful many 
of these publications are when they use these drugs under 
conditions that are impossible to attain in patients.
It is quite possible that silibyn serum concentration will 
be improved with the new pharmaceutical forms under re-
search. Being non-toxic even at high doses, gives a good 
possibility to improve its anti-cancer scope. On the other 
hand, metformin represents an absolute barrier due to its 
toxicity. Achieving a higher plasma concentration will 
only increase the chances of lactic acidosis.
9. Conclusions
Some ongoing research on drug repurposing seems to 
belong more to the realm of Cesare Borgia than to reason-
able and scientific molecular pharmacology. According to 
some not very reliable twisted stories, Borgia was a no-
torious master poisoner in sixteenth century Rome. If we 
poison the cell, it will surely die. Paracelsus cautioned us 
that we must use drugs within their therapeutic range. This 
seems to be ancient history for many twenty first-century 
researchers. 
Some authors take for granted that what happens in the 
Petri dish, no matter the concentration of the drug, will 
also happen in the patients. The problem is that they for-
get that a drug to be effective has to reach its target.
Dose bias and administration route bias seem to repre-
sent a substantial part of present day cancer research.
Finally, we should ask how reliable peer review is, 
when all these supposedly reviewed but heavily biased 
articles pullulate in prestigious journals and in the web.
Paraphrasing Paracelsus: Venenose portione vir necat, 
autem non sanat.
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